Quality of reporting of serious adverse drug events to an institutional review board: A case study with the novel cancer agent, imatinib mesylate

David A. Dorr, Rachel Burdon, Dennis P. West, Jennifer Lagman, Christina Georgopoulos, Steven M. Belknap, June M. McKoy, Benjamin Djulbegovic, Beatrice J. Edwards, Sigmund A. Weitzman, Simone Boyle, Martin S. Tallman, Moshe Talpaz, Oliver Sartor, Charles L. Bennett

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Quality of reporting of serious adverse drug events to an institutional review board: A case study with the novel cancer agent, imatinib mesylate'. Together they form a unique fingerprint.

Medicine & Life Sciences